^
    Back
    Association details:
    Biomarker:MCT1 overexpression
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

    Published date:
    11/12/2021
    Excerpt:
    Patients with high gene expression levels of MCT1 showed significantly reduced PFS (31.9 vs. 48.2 months in MCT1high vs. MCT1low, P=.03) and OS (75.9 months vs. not reached (NR) months in MCT1high vs. MCT1low; P=.001) in case of lenalidomide maintenance...Together, we establish MCT1-expression as a predictive marker for response to lenalidomide-based maintenance treatment.
    DOI:
    10.1182/bloodadvances.2021005532
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma

    Published date:
    11/06/2019
    Excerpt:
    MCT1 expression as potential predictive marker for response to IMiD-based maintenance treatment. Both PFS and OS were significantly reduced in patients with high gene expression levels of MCT1. In vitro and in vivo (xenograft model), MCT1 overexpression reduced sensitivity to lenalidomide unlike bortezomib treatment.
    DOI:
    https://doi.org/10.1182/blood-2019-130734